Market Place
Sourcing Support
Novo Nordisk A/S - share repurchase programme
20 Jan 2025 //
GLOBENEWSWIRE
Novo touts weight loss results in high-dose Wegovy study
18 Jan 2025 //
FIERCE PHARMA
Novo`s Ozempic, Wegovy picked for US Medicare price negotiations
18 Jan 2025 //
REUTERS
Novo Nordisk: Semaglutide Shows 20.7% Weight Loss In Step up Trial
17 Jan 2025 //
GLOBENEWSWIRE
Novo Invests $200M for Windward Bio`s Asthma and COPD Treatments
10 Jan 2025 //
PR NEWSWIRE
Novo Puts $4.6B on the Line to Expand Valo Deal
09 Jan 2025 //
BIOSPACE
Wegovy and Zepbound tipped to fuel $20B heart failure boom
08 Jan 2025 //
FIERCE PHARMA
Novo, Lilly launches top Clarivate`s `Drugs to Watch` list
08 Jan 2025 //
FIERCE PHARMA
SomaScan Assay Drives Insights On Semaglutide Published In Nature
08 Jan 2025 //
GLOBENEWSWIRE
Variant Bio, Novo Nordisk Partner On Metabolic Disease Research
07 Jan 2025 //
PR NEWSWIRE
Novo petitions FDA over Victoza compounding as generic win approval
06 Jan 2025 //
FIERCE PHARMA
Novo, Lilly poised to overcome GLP-1 supply constraints in 2025
02 Jan 2025 //
FIERCE PHARMA
FDA approves Hikma`s generic of Novo`s diabetes drug Victoza
24 Dec 2024 //
REUTERS
US FDA approves Novo Nordisk`s bleeding disorder drug
21 Dec 2024 //
REUTERS
Novo stock crashes after CagriSema misses weight-loss goal
21 Dec 2024 //
FIERCE BIOTECH
Novo to Explore CagriSema Weight-Loss Potential in New Trial
20 Dec 2024 //
REUTERS
Zealand CEO: Novo`s CagriSema Data Supports Monotherapy Approach
20 Dec 2024 //
REUTERS
Weight-Loss Drug Developers Eye $150 Billion Market
20 Dec 2024 //
REUTERS
Novo and Lilly Face Growing Competition from Weight Loss Copies
20 Dec 2024 //
REUTERS
Novo Nordisk A/S - share repurchase programme
20 Dec 2024 //
GLOBENEWSWIRE
Novo Nordisk`s Biologic Alhemo Receives Approval in US
20 Dec 2024 //
FDA
Novo Adds Novel Approach to Cardiometabolic With Photys Collab
19 Dec 2024 //
GLOBENEWSWIRE
Obesity giants will begin $80 bln M&A face-off
19 Dec 2024 //
REUTERS
Novo Holdings Completes Acquisition of Catalent
18 Dec 2024 //
BUSINESSWIRE
Novo Nordisk`s Ozempic faces EU review for potential eye disease connection
18 Dec 2024 //
REUTERS
Nestle launches protein shots for US weight-loss drug
18 Dec 2024 //
REUTERS
FDA warns online vendors selling unapproved weight-loss drugs
18 Dec 2024 //
REUTERS
Novo`s Ozempic faces scrutiny over potential link to rare eye disease
17 Dec 2024 //
REUTERS
Novo invests $1.2 bln in new rare disease drugs plant in Denmark
17 Dec 2024 //
REUTERS
Regulatory conditions on Novo $16.5 billion Catalent deal fulfilled
16 Dec 2024 //
PRESS RELEASE
Novo holding Clears Catalent Buy & 3 Novo Nordisk Sites Acquisitions
14 Dec 2024 //
PRESS RELEASE
Novo Nordisk Snags Kidney Disease Expansion for Ozempic in Europe
14 Dec 2024 //
BIOSPACE
Lilly`s Mounjaro Beats Wegovy In UK Obesity Drug Market
12 Dec 2024 //
REUTERS
Evotec, Novo Nordisk Launch LAB eN(2) Drug Discovery Projects
11 Dec 2024 //
ACCESSWIRE
Eikonizo Therapeutics Announces Investment by Novo for EKZ-102
10 Dec 2024 //
BUSINESSWIRE
Novo Nordisk A/S - share repurchase programme
09 Dec 2024 //
GLOBENEWSWIRE
Novo Holdings` $16.5 bln Catalent buy wins EU antitrust approval
09 Dec 2024 //
PRESS RELEASE
HIBISCUS Phase 2 Data Shows Promise In Sickle Cell Disease
07 Dec 2024 //
PR NEWSWIRE
Novo Nordisk to slash prices of Fiasp, Tresiba in 2026
06 Dec 2024 //
FIERCE PHARMA
Novo`s to cut US list price of 2 insulin products by more than70%
06 Dec 2024 //
PRFESS RELEASE
FDA chief Defends Obesity Work Before Senate RFK Jr Criticism
06 Dec 2024 //
REUTERS
Lilly`s Zepbound Beats Wegovy In Weight Loss Trial: 20.2% Vs. 13.7%
05 Dec 2024 //
PR NEWSWIRE
Novo unveils plans for $400M quality control hub in Denmark
05 Dec 2024 //
FIERCE PHARMA
Novavax sells Czech production plant to Novo Nordisk for $200M
04 Dec 2024 //
FIERCE PHARMA
Novo Presents Data from Sickle Cell & Hemophilia Trials at ASH
03 Dec 2024 //
GLOBENEWSWIRE
Novo Nordisk Highlights Rare Blood Disorders at ASH 2024
03 Dec 2024 //
PR NEWSWIRE
Novo India execs urge early Wegovy launch as weight-loss rival
03 Dec 2024 //
ECONOMICTIMES
Novo Nordisk A/S - share repurchase programme
25 Nov 2024 //
GLOBENEWSWIRE
Thousands turn to Wegovy copies each month as FDA consider shortage
25 Nov 2024 //
REUTERS
Novo Holdings set to win EU nod for $16.5 bln Catalent deal
23 Nov 2024 //
REUTERS
Ypsomed will make injection pens for Novo Nordisk`s CagriSema
22 Nov 2024 //
REUTERS
Novo Nordisk A/S: Trading In Shares By Board Members & Executives
19 Nov 2024 //
GLOBENEWSWIRE
Essence Ph 3 Shows Semaglutide 2.4 mg Benefits for MASH at AASLD
19 Nov 2024 //
PR NEWSWIRE
Novo Nordisk launches obesity drug Wegovy in China
19 Nov 2024 //
REUTERS
Novo Nordisk A/S - share repurchase programme
18 Nov 2024 //
GLOBENEWSWIRE
Novo to gradually phase out production of human insulin pens
16 Nov 2024 //
FIERCE PHARMA
Omega halts sole clinical-stage asset to focus on 3 programs
15 Nov 2024 //
FIERCE BIOTECH
EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 bln deal
13 Nov 2024 //
REUTERS
Novo Nordisk A/S: Trading by Board, Execs & Associates
13 Nov 2024 //
GLOBENEWSWIRE
Novo Nordisk Shares Trading by Executives & Board Members
12 Nov 2024 //
GLOBENEWSWIRE
